Leerink Swann set a $106.00 target price on AbbVie (NYSE:ABBV) in a report released on Tuesday morning. The brokerage currently has a buy rating on the stock. Leerink Swann also issued estimates for AbbVie’s Q1 2018 earnings at $1.56 EPS and Q4 2018 earnings at $1.89 EPS.

Several other equities analysts have also recently weighed in on the company. Jefferies Group raised their price target on AbbVie from $107.00 to $115.00 and gave the company a buy rating in a report on Monday, October 16th. BMO Capital Markets set a $66.00 price target on AbbVie and gave the company a hold rating in a report on Friday, October 27th. BidaskClub upgraded AbbVie from a buy rating to a strong-buy rating in a report on Wednesday, September 6th. Piper Jaffray Companies raised their price target on AbbVie to $115.00 and gave the company an overweight rating in a report on Friday, October 27th. Finally, Zacks Investment Research cut AbbVie from a buy rating to a hold rating in a report on Friday, October 20th. Seven investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $96.66.

Shares of AbbVie (ABBV) opened at $95.41 on Tuesday. The stock has a market capitalization of $152,012.06, a P/E ratio of 17.93, a P/E/G ratio of 1.34 and a beta of 1.52. AbbVie has a 12 month low of $58.80 and a 12 month high of $98.52. The company has a debt-to-equity ratio of 5.08, a quick ratio of 1.32 and a current ratio of 1.45.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.02. The company had revenue of $7 billion for the quarter, compared to the consensus estimate of $7 billion. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the company earned $1.21 EPS. equities analysts forecast that AbbVie will post 5.55 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.98%. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. The ex-dividend date is Thursday, January 11th. AbbVie’s payout ratio is presently 62.29%.

In related news, Chairman Richard A. Gonzalez sold 218,193 shares of the business’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $94.01, for a total transaction of $20,512,323.93. Following the transaction, the chairman now directly owns 492,030 shares in the company, valued at approximately $46,255,740.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $85.02, for a total value of $705,666.00. Following the transaction, the senior vice president now owns 93,099 shares in the company, valued at $7,915,276.98. The disclosure for this sale can be found here. Over the last three months, insiders sold 277,125 shares of company stock valued at $25,891,756. Corporate insiders own 0.23% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Shelton Capital Management raised its holdings in shares of AbbVie by 59.6% during the third quarter. Shelton Capital Management now owns 127,799 shares of the company’s stock valued at $11,356,000 after acquiring an additional 47,700 shares during the last quarter. GSB Wealth Management LLC acquired a new position in shares of AbbVie during the third quarter valued at approximately $240,000. Steward Partners Investment Advisory LLC acquired a new position in shares of AbbVie during the third quarter valued at approximately $5,754,000. Public Employees Retirement System of Ohio raised its holdings in shares of AbbVie by 0.4% during the third quarter. Public Employees Retirement System of Ohio now owns 1,101,377 shares of the company’s stock valued at $97,868,000 after acquiring an additional 4,028 shares during the last quarter. Finally, Coastline Trust Co raised its holdings in shares of AbbVie by 9.8% during the third quarter. Coastline Trust Co now owns 19,600 shares of the company’s stock valued at $1,742,000 after acquiring an additional 1,744 shares during the last quarter. Institutional investors and hedge funds own 69.32% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “AbbVie (ABBV) Given a $106.00 Price Target by Leerink Swann Analysts” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/06/abbvie-abbv-given-a-106-00-price-target-by-leerink-swann-analysts.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.